59 related articles for article (PubMed ID: 38455039)
1. Treatment of multiple myeloma.
San Miguel JF; Bladé Creixenti J; García-Sanz R
Haematologica; 1999 Jan; 84(1):36-58. PubMed ID: 10091392
[TBL] [Abstract][Full Text] [Related]
2. Advances in biology and therapy of multiple myeloma.
Barillé-Nion S; Barlogie B; Bataille R; Bergsagel PL; Epstein J; Fenton RG; Jacobson J; Kuehl WM; Shaughnessy J; Tricot G
Hematology Am Soc Hematol Educ Program; 2003; ():248-78. PubMed ID: 14633785
[TBL] [Abstract][Full Text] [Related]
3. CD200 genotype is associated with clinical outcome of patients with multiple myeloma.
Gonzalez-Montes Y; Osca-Gelis G; Rodriguez-Romanos R; Villavicencio A; González-Bártulos M; Llopis F; Clapes V; Oriol A; Sureda A; Escoda L; Sarrà J; Garzó A; Lloveras N; Gómez B; Granada I; Gallardo D
Front Immunol; 2024; 15():1252445. PubMed ID: 38455039
[TBL] [Abstract][Full Text] [Related]
4. The role of positron emission tomography with 18F-fluorodeoxyglucose integrated with computed tomography in the evaluation of patients with multiple myeloma undergoing allogeneic stem cell transplantation.
Patriarca F; Carobolante F; Zamagni E; Montefusco V; Bruno B; Englaro E; Nanni C; Geatti O; Isola M; Sperotto A; Buttignol S; Stocchi R; Corradini P; Cavo M; Fanin R
Biol Blood Marrow Transplant; 2015 Jun; 21(6):1068-73. PubMed ID: 25754658
[TBL] [Abstract][Full Text] [Related]
5. Clinical significance of CD200 expression in newly diagnosed multiple myeloma patients and dynamic changing during treatment.
Shi Q; Wu C; Han W; Zhao S; Wu Y; Jin Y; Qu X; Li J; Zhang R; Chen L
Leuk Lymphoma; 2021 Mar; 62(3):709-715. PubMed ID: 33108911
[TBL] [Abstract][Full Text] [Related]
6. Survival of multiple myeloma patients aged 65-70 years in the era of novel agents and autologous stem cell transplantation. A multicenter retrospective collaborative study of the Japanese Society of Myeloma and the European Myeloma Network.
Ozaki S; Harada T; Saitoh T; Shimazaki C; Itagaki M; Asaoku H; Kuroda Y; Chou T; Yoshiki Y; Suzuki K; Murakami H; Hayashi K; Mina R; Palumbo A; Shimizu K; ;
Acta Haematol; 2014; 132(2):211-9. PubMed ID: 24662986
[TBL] [Abstract][Full Text] [Related]
7. Tandem Autologous Stem Cell Transplantation Improves Outcomes in Newly Diagnosed Multiple Myeloma with Extramedullary Disease and High-Risk Cytogenetics: A Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.
Gagelmann N; Eikema DJ; Koster L; Caillot D; Pioltelli P; Lleonart JB; Reményi P; Blaise D; Schaap N; Trneny M; Passweg J; Porras RP; Cahn JY; Musso M; Poiré X; Fenk R; Itälä-Remes M; Pavone V; Fouillard L; Maertens J; Bron D; Pouli A; Schroyens W; Schönland S; Garderet L; Yakoub-Agha I; Kröger N
Biol Blood Marrow Transplant; 2019 Nov; 25(11):2134-2142. PubMed ID: 31288095
[TBL] [Abstract][Full Text] [Related]
8. Genetic variants of CTLA4 are associated with clinical outcome of patients with multiple myeloma.
Gonzalez-Montes Y; Rodriguez-Romanos R; Villavicencio A; Osca-Gelis G; González-Bártulos M; Llopis F; Clapes V; Oriol A; Sureda A; Escoda L; Sarrà J; Garzó A; Lloveras N; Díez I; Granada I; Gallardo D
Front Immunol; 2023; 14():1158105. PubMed ID: 37122695
[TBL] [Abstract][Full Text] [Related]
9. The immunoregulatory protein CD200 as a potentially lucrative yet elusive target for cancer therapy.
Shao A; Owens DM
Oncotarget; 2023 Feb; 14():96-103. PubMed ID: 36738455
[TBL] [Abstract][Full Text] [Related]
10. Minimal Residual Disease in Multiple Myeloma: Ready for Prime Time?
Mina R; Bonello F; Oliva S
Cancer J; 2021 May-Jun 01; 27(3):247-255. PubMed ID: 34549914
[TBL] [Abstract][Full Text] [Related]
11. Deregulated Expression of Immune Checkpoints on Circulating CD4 T Cells May Complicate Clinical Outcome and Response to Treatment with Checkpoint Inhibitors in Multiple Myeloma Patients.
Kulikowska de Nałęcz A; Ciszak L; Usnarska-Zubkiewicz L; Frydecka I; Pawlak E; Szmyrka M; Kosmaczewska A
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502204
[TBL] [Abstract][Full Text] [Related]
12. Immune System Alterations in Multiple Myeloma: Molecular Mechanisms and Therapeutic Strategies to Reverse Immunosuppression.
Díaz-Tejedor A; Lorenzo-Mohamed M; Puig N; García-Sanz R; Mateos MV; Garayoa M; Paíno T
Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33802806
[TBL] [Abstract][Full Text] [Related]
13. CD200:CD200R Interactions and Their Importance in Immunoregulation.
Kotwica-Mojzych K; Jodłowska-Jędrych B; Mojzych M
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33562512
[TBL] [Abstract][Full Text] [Related]
14. Multiple myeloma.
van de Donk NWCJ; Pawlyn C; Yong KL
Lancet; 2021 Jan; 397(10272):410-427. PubMed ID: 33516340
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
